- Charles B Wilson, director (wilsonc@neuro.ucsf.edu)ab
- a Institute for the Future, Menlo Park, CA 94025-7020, USA
- b Correspondence to: Department of Neurosurgery, University of California at San Francisco, San Francisco, CA 94143-0350, USA
During the next decade diseases requiring medical intervention will be much the same as those being treated today. The site of care may, however, be moved away from the community general hospital to a non-hospital site or to a higher order or specialty hospital at a distance.
With the applications of technological advances, procedures that once were performed in hospitals are now done in free standing facilities, accelerating a trend that began in the United States in the 1980s with the introduction of magnetic resonance imaging, fibreoptic endoscopes and arthroscopes, and ambulatory surgicentres. Just as the discovery and successful treatment of Helicobacter pylori for peptic ulcer replaced a commonly performed operation so new advances will eliminate the need for care once provided by hospitals, and hospitals will become places that treat conditions that cannot be treated in other settings.
Summary points
Pharmaceuticals will replace some procedures and will decrease the need for admission to hospital, and newer vaccines will treat as well as prevent disease
Minimally invasive surgery will reduce hospital stay and promote outpatient operations
Sensors will change central laboratories and intensive care units of today
Digitised images will be accessible to all clinicians
Xenotransplantation from transgenic pigs is ever more likely
Economics and superior outcomes will favour specialty hospitals
Pharmaceuticals
An abundance of new pharmaceuticals will alleviate a wide range of common diseases that account for a large proportion of patients currently admitted to hospital for inpatient care. New pharmaceuticals will reduce the incidence of atherosclerosis, coronary artery disease, and in particular stroke. Other pharmaceutical advances will promote the opening of stenotic arteries and the dissolution of acute thrombi Biotechnology companies are developing products that will prevent, modify, or treat a variety of cancers—breast cancer being one of the first treated.1 2 How significantly pharmaceuticals will affect infectious diseases, and …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record







CiteULike
Connotea
Del.icio.us
Digg
Facebook
Mendeley
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: Ventilator associated pneumonia
Published 30 May 2012
Re: Restless legs syndrome
Published 30 May 2012
Author's reply
Published 30 May 2012
Re: Full access to trial data holds many benefits and a few pitfalls, conference hears
Published 30 May 2012
Restless Legs Syndrome: Fact or Fiction
Published 30 May 2012
Most responses
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 (12 responses)
Published 10 May 2012 - 23:32
The psychiatric oligarchs who medicalise normality (9 responses)
Published 2 May 2012 - 15:42
Are doctors justified in taking industrial action in defence of their pensions? No (8 responses)
Published 8 May 2012 - 12:21
Are doctors justified in taking industrial action in defence of their pensions? Yes (8 responses)
Published 8 May 2012 - 12:21
The hardest thing: admitting error (7 responses)
Published 2 May 2012 - 12:27